Renephra Ltd is a medical device company developing a groundbreaking Transdermal Fluid Removal (TFR) technology for minimally invasive fluid removal.
We are targeting the significant problems of fluid overload and chronic oedema / lymphoedema in vascular, oncology and other disease areas.
This is a substantial patient group with unmet clinical needs and is an estimated £1billion market worldwide.
Having achieved proof of concept in humans, Renephra is raising £300k to conduct device development study and design feasibility.
March 2018 | EIS Investment Opportunity for Private Investors
We now have a £70k EIS investment opportunity for private investors, following an investment of £231k supported by our lead investors Deepbridge Capital and Catapult Ventures to bring us up to £300k. The minimum investment sought is £70k with an overfunding up to £330k. Find out more...
February 2018 | New Investment
Renephra has received investment from Deepbridge Capital, Catapult Ventures, and private investors.
December 2017 | Innovate UK
Renephra has been awarded a £90k Biomedical Catalyst Feasibility Studies award.
December 2017 | British Heart Foundation Translational Award
Our Transdermal Fluid Removal development study has received funding support from the British Heart Foundation
June 2015 | MedTech Strategist
Start-Ups to Watch: “Renephra. Home-Based Fluid Removal for Fluid Overload and Chronic Edema.” by Mary Stuart.
© 2018 Renephra Ltd. All rights reserved.